Annotation Detail
Information
- Associated Genes
- BRCA1
- Associated Variants
-
BRCA1 LOSS-OF-FUNCTION
BRCA1 LOSS-OF-FUNCTION - Associated Disease
- ovarian cancer
- Source Database
- CIViC Evidence
- Description
- A phase 2 trial on patients with relapsed, platinum-sensitive high grade ovarian carcinoma (ARIEL2 Part1, NCT01891344) was held to assess PARP inhibitor Rucaparib on 3 genetically defined subsets of patients. Out of 40 BRCA mutant patients, 10 had somatic BRCA1 mutation. Confirmed objective response was seen in 79% of the BRCA1 mutant subgroup, and 74% confirmed objective response was seen in the somatic BRCA mutant subgroup. In a BRCA wild-type subgroup, with low levels of Loss of Heterozygosity, confirmed objective response was observed in 10% of the patients.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1897
- Gene URL
- https://civic.genome.wustl.edu/links/genes/6
- Variant URL
- https://civic.genome.wustl.edu/links/variants/185
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Ovarian Cancer
- Evidence Direction
- Supports
- Drug
- Rucaparib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 27908594
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Rucaparib | Sensitivity | true |